Medical Condition News

RSS

Clues to prostate cancer risk in blood samples taken 15 years earlier

Recent study links blood proteins to aggressive prostate cancer, identifying potential biomarkers for early risk prediction and insights into immune activity.

26 Oct 2026

Geriatric chronic kidney disease patients benefit from SGLT2 inhibition

New research uncovers the potential benefits and risks of sodium-glucose cotransporter 2 (SGLT2) inhibitors for adults aged 80 years or older with chronic kidney disease (CKD). The findings will be presented at ASN Kidney Week 2026 October 22–25.

26 Oct 2026

Next generation KRAS inhibitor divarasib significantly extends lung cancer survival

Patients with previously treated advanced KRAS G12C-mutant non-small cell lung cancer (NSCLC) lived significantly longer and saw improved disease control when treated with the next-generation KRAS targeted therapy divarasib, according to researchers from The University of Texas MD Anderson Cancer Center.

26 Oct 2026

Phase 3 EMT2 trial demonstrates survival benefit for high-dose EPA

Patients assigned to receive high-dose eicosapentaenoic acid (EPA), an omega-3 fatty acid, before and after surgery for colorectal cancer liver metastases had longer overall survival than those assigned to receive placebo, according to results of the phase 3 EMT2 trial presented at the ESMO Congress 2026.

26 Oct 2026

Women in perimenopause report more anxiety than other menopausal groups

Researchers reviewed 21 studies involving 24,523 women and found that perimenopausal and postmenopausal women had higher odds of reporting anxiety symptoms than premenopausal women. Their meta-analysis of 15 studies found the highest odds during perimenopause, but the cross-sectional evidence cannot establish that menopause causes anxiety.

25 Oct 2026

Personalized mRNA cancer vaccine cuts melanoma recurrence risk when added to immunotherapy

Adding a personalized mRNA-based cancer vaccine to immunotherapy after surgery for high-risk melanoma reduced the risk of recurrence or death by 42%, according to results from the phase 3 INTerpath-001 trial presented at the ESMO Congress 2026.

24 Oct 2026

Drug combination delivers promising survival gains in advanced endometrial cancer

An immunotherapy-based regimen combining durvalumab and the PARP inhibitor, olaparib, demonstrated encouraging long-term survival outcomes for patients with advanced or recurrent endometrial cancer, according to new trial results presented by researchers from The University of Texas MD Anderson Cancer Center.

24 Oct 2026

Kidney Week 2026 features late-breaking clinical trials in kidney care

The American Society of Nephrology, has selected the following late breaking clinical trials to be presented in-person at Kidney Week 2026 October 22–25.

24 Oct 2026

Study: Cats on vegan diets show lower rates of obesity

A large-scale survey has found cats fed vegan diets had lower rates of obesity and related health problems, than those fed conventional meat-based diets.

24 Oct 2026

LGBTQ+ college students facing discrimination report higher mental health risks

LGBTQ+ college students who experience discrimination are significantly more likely to experience depression, anxiety, suicidal thoughts, and avoid needed health care, according to a new national study by Columbia University Mailman School of Public Health, Boston University School of Public Health and Harvard Pilgrim Health Care Institute.

23 Oct 2026

Six-gene score could improve survival predictions for acute myeloid leukemia

The activity of six different genes can help determine patient survival of acute myeloid leukemia (AML), according to a study published today in Science Advances.

23 Oct 2026

Study reveals how cancer cells survive chemotherapy in a zombie-like state

Scientists at Trinity College Dublin have made an important breakthrough in understanding how cancer cells can evade the cell-killing effects of chemotherapy and enter a "zombie-like state", called premature senescence, that can attract the wound healing properties of the immune system.

23 Oct 2026

Nephrologist shortages linked to higher kidney disease mortality along US-Mexico borde

New research indicates that US-Mexico border counties experience disproportionately elevated rates of death from chronic kidney disease (CKD), alongside reduced availability of nephrologists. The findings will be presented at ASN Kidney Week 2026 October 22–25.

23 Oct 2026

New guidance expands reproductive care for people with cystic fibrosis

For much of the history of cystic fibrosis (CF) care, reproductive health was not a major part of the conversation. Fertility challenges were the norm for men and women with this genetic disorder, and many grew up assuming biological parenthood was not possible.

23 Oct 2026

Novel immunosuppressant improves kidney function and quality of life after transplantation

The Phase 2 BESTOW clinical trial showed that tegoprubart (a novel anti-CD40L antibody therapy) was better at preserving kidney function than tacrolimus (the current standard of care) in immunosuppressive regimens in adults receiving their first kidney transplant.

23 Oct 2026

Common kidney tests underestimate chronic kidney disease in cancer patients

New research indicates that commonly used measures of kidney function largely underestimate the prevalence of chronic kidney disease (CKD) in patients with cancer. The findings will be presented at ASN Kidney Week 2026 October 22–25.

23 Oct 2026

KRAS-targeting vaccine prompts immune responses in pancreatic cancer patients

An investigational vaccine helped the immune system recognize and respond to mutations that drive most pancreatic cancers, according to results from a randomized phase 2 clinical trial led by Mayo Clinic researchers.

23 Oct 2026

Digital tools and phone coaching boost cancer genetic testing uptake

About 10% of cancers are linked to an inherited genetic variant, but as few as 1 in 15 cancer patients eligible for genetic testing complete it.

23 Oct 2026

Targeted drug extends survival across diverse pancreatic cancer patient groups

A new analysis of a phase 3 clinical trial found that the targeted drug daraxonrasib improved survival compared with standard chemotherapy across multiple groups of patients with advanced pancreatic cancer, including those with different RAS mutations and those without an identified RAS mutation.

23 Oct 2026

EEG monitoring offers new way to detect cybersickness

For years, developers of virtual reality (VR) and augmented reality (AR) technologies have worked to address an unwanted side effect many users experience: cybersickness, a type of motion sickness triggered by moving digital content.

23 Oct 2026